To determine whether the 12-month intracranial relapse rate following HA-PCI is non-inferior compared to the rate following PCI for patients with SCLC. To determine whether HA-PCI reduces the likelihood of 6-month deterioration from baseline in HVLT-R delayed recall compared to the PCI for patients with SCLC.
Histologic proof or unequivocal cytologic proof (fine needle aspiration, biopsy or two positive sputa) of SCLC within 250 days prior to Step 1 registration; Zubrod performance status 0-2; Patients who are primary English or French speakers are eligible.
21st Century Oncology will be moving to their new home as part of the global GenesisCare network. The 21st Century Oncology website will no longer exist after November 2020.
There will be no disruption in your care team, location, or contacts. There will simply be a new website, new look and feel, and patients will benefit from the latest treatment technology and evidence-based cancer care. We look forward to serving you as part of the GenesisCare team.